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Objectives The purpose of the study was to determine the efficacy and safety of left atrial appendage (LAA) closure via a
percutaneous LAA ligation approach.
Background Embolic stroke is the most devastating consequence of atrial fibrillation. Exclusion of the LAA is believed to de-
crease the risk of embolic stroke.
Methods Eighty-nine patients with atrial fibrillation were enrolled to undergo percutaneous ligation of the LAA with the
LARIAT device. The catheter-based LARIAT device consists of a snare with a pre-tied suture that is guided epicar-
dially over the LAA. LAA closure was confirmed with transesophageal echocardiography (TEE) and contrast fluo-
roscopy immediately, then with TEE at 1 day, 30 days, 90 days, and 1 year post-LAA ligation.
Results Eighty-five (96%) of 89 patients underwent successful LAA ligation. Eighty-one of 85 patients had complete clo-
sure immediately. Three of 85 patients had a 2-mm residual LAA leak by TEE color Doppler evaluation. One of
85 patients had a 3-mm jet by TEE. There were no complications due to the device. There were 3 access-
related complications (during pericardial access, n  2; and transseptal catheterization, n  1). Adverse events
included severe pericarditis post-operatively (n  2), late pericardial effusion (n  1), unexplained sudden death
(n  2), and late strokes thought to be non-embolic (n  2). At 1 month (81 of 85) and 3 months (77 of 81)
post-ligation, 95% of the patients had complete LAA closure by TEE. Of the patients undergoing 1-year TEE
(n  65), there was 98% complete LAA closure, including the patients with previous leaks.
Conclusions LAA closure with the LARIAT device can be performed effectively with acceptably low access complications
and periprocedural adverse events in this observational study. (J Am Coll Cardiol 2013;62:108–18)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.046Atrial fibrillation (AF) is the most common cardiac arrhyth-
mia in the world, with an estimated prevalence of over 3
million people in the United States (1). AF carries a
significantly increased risk of morbidity and mortality, with
embolic stroke being the most severe manifestation. In
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accepted June 12, 2012.patients with AF, there is a 5-fold increased incidence of
embolic stroke (2). The risk of embolic stroke in the general
population increases with age. Therefore, AF is one of the
most important causes of embolic stroke in people over the
age of 75 years (3).
See page 119
Currently, oral anticoagulation therapy is the most effec-
tive available prophylactic approach in patients with AF at
high risk of thromboembolic events (4,5). Unfortunately, only
50% to 60% of patients on warfarin are in the therapeutic range
(6,7), whereas the overall withdrawal rate from warfarin therapy is
10% to 38% after 1 year (8,9). Additionally, contraindications to or
refusal of warfarin therapy adds to the difficulty in providing
effective long-term anticoagulation (10,11). Dabigatran, apixaban,
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July 9, 2013:108–18 Left Atrial Appendage Closure With the LARIAT Sutureand rivaroxaban are new oral anticoagulant agents that have
demonstrated noninferiority and/or superiority to warfarin in
embolic stroke prevention (8,12–14). However, these agents are
still associated with potential bleeding complications, high
cost, and unlike warfarin, there is no antagonist. As the risk
of major bleeding events increases with age, potential
contraindications to anticoagulation therapy increases (15).
Surgical exclusion of the left atrial appendage (LAA) has
been advocated for patients intolerant to warfarin therapy
and as a routine part of the maze procedure due to the
LAA’s propensity for thrombus formation in AF patients
(16). Prophylactic exclusion of the LAA is also recom-
mended during mitral valve surgery as a means of eliminat-
ing a potential source of thromboembolic events (16).
However, successful LAA surgical exclusion can be variable,
with incomplete closure failing to eliminate the risk of
thromboembolic events (17–19). In addition, surgical LAA
exclusion can be complicated by post-operative bleeding
events, perioperative stroke, and LAA laceration with the
application of traction to the appendage (20–22).
A percutaneous approach for exclusion of the LAA is
desirable due to the invasive nature and morbidity associated
with surgical exclusion (20,21). The Watchman trial dem-
onstrated that an LAA occlusion device is noninferior to
warfarin for preventing embolic stroke in AF patients;
however, concerns in regard to device embolization, tam-
ponade, and periprocedural stroke have delayed its approval
by the U.S. Food and Drug Administration (23). Recently,
a percutaneous approach using an epicardial suture has been
developed for exclusion of the LAA (24–26). The procedure
has been shown to be feasible in humans, but its long-term
efficacy and safety remains unknown. In this study, we report
the efficacy and 1-year clinical results of LAA closure via a
percutaneous epicardial suture ligation approach.
Methods
Patient population. Patients ages 35 to 81 years were
identified and enrolled between December 2009 and De-
cember 2010 for closure of the LAA. The protocol was
conducted with the approval of the Polish Ministry of
Health and the ethics committee at John Paul II Hospital,
Krakow, Poland.
Eligible patients met all of the following inclusion crite-
ria: 1) age 18 years or older; 2) nonvalvular AF; 3) at least 1
risk factor of embolic stroke (CHADS2 1); 4) a poor
andidate or ineligible for warfarin therapy (e.g., labile
nternational normalized ratio level, noncompliant, contra-
ndicated) and/or a warfarin failure (i.e., transient ischemic
ttack or stroke while on warfarin therapy); and 5) a life
xpectancy of at least 1 year (Table 1).
Patients were excluded from the study if they met any of
he following exclusion criteria: 1) history of pericarditis;
) history of cardiac surgery; 3) pectus excavatum; 4) recent
yocardial infarction within 3 months; 5) prior embolicvent within the last 30 days; 6) New York Heart Associ- ation functional class IV heart
ailure symptoms; 7) left ventric-
lar function 30%; and 8) his-
ory of thoracic radiation. Pa-
ients meeting the criteria for the
tudy enrollment underwent a
creening contrast cardiac com-
uted tomography (CT) scan. Ad-
itional exclusion criteria based on
AA anatomy included: 1) a
AA width 40 mm; 2) a supe-
iorly oriented LAA with the
AA apex directed behind the pulmonary trunk; 3) bilobed
AA or multilobed LAA in which lobes were oriented in
ifferent planes exceeding 40 mm; and 4) a posteriorly
otated heart.
ercutaneous suture ligation of LAA. The device (Sentre
EART, Redwood City, California) for exclusion of the
AA consists of 3 components: 1) a 15-mm compliant
cclusion balloon catheter (EndoCATH); 2) 0.025-inch
nd 0.035-inch magnet-tipped guidewires (FindrWIRZ);
nd 3) a 12-F suture delivery device (LARIAT) (24–26)
Fig. 1). The procedure involves 4 basic steps: 1) pericardial
nd transseptal access; 2) placement of the endocardial
agnet-tipped guidewire in the apex of the LAA with
Abbreviations
and Acronyms
AF  atrial fibrillation
CT  computed
tomography
IQR  interquartile range
LAA  left atrial
appendage
TEE  transesophageal
echocardiography
Baseline Characteristics (N  89)Table 1 Baseline Characteristics (N  89)
Variable Intent-to-Treat Cohort
Age, yrs 62 10
Sex
Male 51 (57%)
Female 38 (43%)
Atrial fibrillation
Paroxysmal 30 (34%)
Persistent 59 (66%)
Congestive heart failure 11 (12%)
Hypertension 84 (94%)
Age 75 yrs 11 (12%)
Diabetes mellitus 9 (10%)
Stroke/transient ischemic attack while on OAC 22 (25%)
Failure/complication* while on OAC 12 (13%)
Contraindicated to OAC 5 (5.6%)
Labile INR 57 (64%)
Coronary artery disease 4 (4%)
Left atrial appendage characteristics
Width, mm† 26 7.4
Length, mm‡ 32 7.4
Number of lobes 2.0 0.74
Pre-ligation medication
Warfarin 84 (94%)
Aspirin 2 (2%)
Clopidogrel 2 (2%)
Aspirin  clopidogrel 1 (1%)
Values are mean  SD or n (%). *Failure of OAC: history of left atrial/left atrial appendage
thrombus despite OAC; complication of OAC: history of bleeding complication with OAC. †Measured
as maximal left atrial appendage width. ‡Measured from the left atrial appendage apex to base.INR  international normalized ratio; LAA 
nticoagulation.left atrial appendage; OAC  oral
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epicardial and endocardial magnet-tipped guidewires for
stabilization of the LAA; and 4) snare capture of the LAA
with closure confirmation and release of the pre-tied suture
for LAA ligation.
Patients were prepped and draped with sterile preparation
of the subxiphoid and bilateral groin regions. Once the
patient was anesthetized, transesophageal echocardiography
(TEE) was performed to rule out LAA thrombus. The
3-dimensional cardiac CT reconstruction was used to guide
Figure 1 Components for the
Percutaneous LAA Ligation Procedure
The components of the percutaneous left atrial appendage (LAA) ligation proce-
dure include: (A) a 0.025-inch endocardial magnet-tipped and 0.035-inch epi-
cardial magnet-tipped guidewire, each with a magnet of opposite polarity
enabling an end-to-end alignment; (B) a 15-mm compliant occlusion balloon
catheter to identify the LAA os with TEE; (C) the LARIAT suture delivery device.
The higher-power inset demonstrates the pre-tied size 0 Teflon-coated, braided
polyester suture (blue) mounted within a radiopaque adjustable snare. (D) use
of the components as a system to ligate the LAA.
Figure 2 3D CT Reconstruction
Cardiac 3-dimensional (3D) computed tomography (CT) reconstruction is used for
CT reconstruction aids in the guidance of the pericardial access by approximating
device has a slight bend at the distal end to allow for the device to curve from an
the snare to advance over the LAA. The majority of LAAs are directed anteriorly. H
direction of the pericardial needle. Additionally, the lateral view of the CT allows fo
anterior aspect of the myocardium. This view helps with the steepness of the dire
sternum is in relationship to the inferior aspect of the myocardium. This allows fo
to obtain pericardial access. Blue lines  LARIAT suture delivery device. AP  antpericardial access (Fig. 2). Pericardial access using a 17-G
epidural needle was performed as previously described (27).
The epicardial puncture was performed with the goal of
achieving access to the anterior surface of the heart. An
anterior epicardial puncture facilitated an anterior and
inferior approach with the LARIAT snare over the LAA
apex to its base. Anterior-posterior and lateral fluoroscopic
views were used to guide the needle for epicardial puncture.
Once epicardial access was confirmed, a 0.35-inch guide-
wire was left in the pericardial space while a transseptal
catheterization was performed. Five thousand units of
heparin were administered intravenously once the transsep-
tal catheterization was completed. An additional 2,000 U of
heparin were administered intravenously every 45 min for
prolonged procedures. An activated clotting time was not
obtained due to the lack of available equipment. The
transseptal sheath was flushed with heparinized saline every
5 min. An 8.5-F SL1 catheter (St. Jude Medical, St. Paul,
Minnesota) was directed anteriorly in the left atrium toward
the LAA. A left atriagram was performed in the right
anterior oblique view to delineate the ostium and body of
the LAA (Fig. 3A). The 15-mm occlusion balloon catheter
(EndoCATH) was back-loaded with a magnet-tipped
0.025-inch endocardial guidewire (FindrWIRZ) and in-
serted to the end of the SL1 transseptal catheter. The
endocardial magnet-tipped guidewire was advanced to the
apex of the LAA under fluoroscopic guidance. To navigate
the endocardial guidewire, a mild bend was placed at
the end of the guidewire to allow steerability of the
endocardial guidewire. The balloon catheter was then ad-
vanced over the wire into the LAA. An LAA angiogram
(appendagram) was performed through the lumen of the
balloon catheter to evaluate the endocardial guidewire
ining the size, shape, and orientation of the left atrial appendage (LAA). The 3D
erior anterior approach of the LARIAT suture device. The LARIAT suture delivery
o posterior around the cardiac surface to approach the LAA inferiorly and allow
, in some instances, the LAA is posteriorly rotated, necessitating a more lateral
re-procedural assessment of the amount of space between the sternum and
f the pericardial needle. Finally, the CT allows for assessment of how inferior the
-procedure assessment of how far the pericardial needle will need to be inserted
osterior view; AP/Lat  anterior-posterior/lateral view; Lat  lateral view.determ
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location. The epicardial access site was then sequentially
dilated over the guidewire for placement of the 14-F
soft-tipped epicardial guide cannula (SentreHEART). The
0.035-inch epicardial magnet-tipped guidewire was placed
through the epicardial sheath for the goal of achieving an
end-to-end magnetic union with the endocardial guidewire
(Fig. 3B). The attached magnet-tipped guidewires act as a
controlled pathway for delivery of the LARIAT snare to the
base of the LAA without the need for traction or grasping
of the delicate LAA tissue (Fig. 3C). Once the LARIAT
suture delivery device was positioned over the LAA, the
endoCATH balloon was used to position the snare at the
ostium of the LAA. TEE was used to verify the anatomic
position of the endoCATH balloon at the ostium of the
LAA (Fig. 4B). After confirmation of the balloon catheter
at the LAA ostium, the snare was closed (Fig. 3D). A left
atriagram was performed to confirm complete capture of the
LAA and rule out the existence of a remnant trabeculated
LAA (Fig. 3E). After verifying LAA capture, the pre-
loaded suture was released from the snare and tightened to
exclude the LAA. Tightening was completed using a
suture-tightening device that eliminates operator variabil-
ity during tightening (TenSURE, SentreHEART). The
Figure 3 Fluoroscopic Guidance to Assist in the Closure of the
All images are in the right anterior oblique projection. Left atrial (LA) angiography i
magnet-tipped endocardial and epicardial guidewires (B) allows for the LARIAT sut
using an over-the-wire approach (C). After verification of the correct position of the
of the pre-tied suture to exclude the existence of a remnant trabeculated LAA lobe
for the LARIAT LAA ligation procedure.LARIAT snare was removed from the pericardial space.The suture was cut near the LAA with a suture cutter
(SentreHEART) that was passed over the suture. A pigtail
catheter was placed in the pericardial space for at least 6 h
and more commonly overnight. The pericardial catheter was
attached to low suction to assess for any periprocedural
pericardial effusions. A transthoracic echocardiogram was per-
formed to rule out a pericardial effusion before the pericardial
catheter was removed.
Clinical follow-up. TEE was performed at 1 day, 30 days,
90 days, and 1 year post-LAA ligation. Following the
procedure, the patients were observed in the intensive care
unit overnight. The patients were then sent to a telemetry
floor for 2 days before discharge. Clinical follow-up by the
investigators were via phone contact at 1 month, and
outpatient appointments performed at 6 months and 1 year
post-ligation. Additionally, patients were followed by their
referring physicians within 1 month of the procedure.
Patients with a contraindication to warfarin remained off
warfarin. It was recommended that patients with a
CHADS2 score of 2 or higher who could tolerate warfarin
(i.e., noncompliant or labile international normalized ratio
level) continue warfarin. Warfarin use in patients with a
CHADS2 score of 1 was left to the discretion of the
referring physician. For patients not on warfarin, aspirin
es the ostium and body of the left atrial appendage (LAA) (A). Attachment of the
livery device to be guided over the LAA by the magnet-tipped epicardial guidewire
with the balloon catheter (D), an LA angiogram is performed prior to the release
final LA angiogram is performed to verify LAA exclusion (F). See Online Video 1LAA
dentifi
ure de
snare
(E). Atherapy was recommended.
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ables are expressed as mean  SD. Continuous variables
that were not normally distributed are expressed as median
(interquartile ranges [IQR]).
Results
The initially screened population consisted of 119 patients
satisfying inclusion criteria for LAA ligation. After evalua-
tion of the pre-procedural CT scan, 16 patients were
excluded due to LAA size (8 patients with LAA width 40
mm) or morphology (n 8) contraindications (Fig. 5). The
redominant LAA shape that led to exclusion was a
uperior-posterior orientation of the LAA apex, commonly
ith the apex behind the pulmonary artery. Of the remain-
ng 103 patients, 11 patients were excluded due to an LAA
hrombus on pre-procedural TEE. Of the 92 patients who
roceeded to LAA ligation, 3 patients were excluded
ecause of pericardial adhesions precluding pericardial ac-
ess. These adhesions were noted to obstruct the passage of
he epicardial guidewire in the pericardial space. Pericardial
Figure 4 TEE Guidance for the Closure of the LAA
Transesophageal echocardiography (TEE) imaging of the LA and LAA at baseline (A
used to define the orifice of the LAA and ensure that closure is distal (red line) to
the LAA following ligation of the LAA (C). TEE performed 30 days after the immedidhesions were confirmed with contrast injection into thepericardial space. The procedure was subsequently aborted
for these 3 patients. Table 1 describes the baseline charac-
teristics of the 89 patients for whom LAA ligation was
attempted. Table 2 describes the thromboembolic and
leeding event risk characteristics of our cohort as reflected
n the CHADS2, CHA2DS2-VASc (28), and HAS-BLED
(29) scores.
Immediate LAA closure was achieved in 85 of 89 patients
attempted (Table 3). Complete closure was achieved in 96%
of successful LAA ligations. Complete closure was defined
as a 1-mm jet by color flow Doppler. TEE performed 1
day, 30 days, and 90 days after the procedure revealed
complete closure in 95% of patients in whom LAA ligation
was attempted. Four patients had a 2-month TEE and
refused the 3-month TEE follow-up. There was only 1
patient that had an increase in leakage 1 day after the
procedure (Table 3). In 1 patient, color Doppler echocar-
diography increased from 1- to a 2-mm color Doppler
jet, but remained stable at 1-month and 3-month follow-up.
No patients had a3-mm jet by color Doppler at 3 months.
during the placement of the balloon at the orifice of the LAA (B). The balloon is
ronary sinus (arrow). Color Doppler is used to verify the immediate closure of
sure verifies persistent closure of the LAA (D). Abbreviations as in Figure 3.) and
the co
ate cloAt the 3-month TEE, there was no color Doppler evidence
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The patients with a 2- or 3-mm residual channel at day 1,
ay 30, and day 90 were the same patients. Complete
losure of the LAA was seen in 98% of patients undergoing
-year follow-up TEE. This included all patients that had a
- to 3-mm color Doppler leak noted at the 3-month TEE.
ne patient that had a 2-mm color Doppler leak at 3
months was found to still have a 2-mm color Doppler
leak. Thrombus formation was not detected at the site of
occlusion by TEE throughout the follow-up period. In 1
patient at the 1-year follow-up TEE, there was a thrombus
in the left atrium at a site distant from the occlusion site.
The patient had stopped her warfarin after the initial LAA
Figure 5 Flow Diagram of Patients Screened for LAA Exclusion
*Mobile thrombus considered a temporary exclusion. Patients placed on OAC unti
ulation; RA  right atrium; RV  right ventricle.
Thromboembolic and Bleeding Risk Scores (N  89)Table 2 Thromboembolic and Bleeding Risk Scores (N  89)
Score CHADS2 CHA2DS2-VASc HAS-BLED
0 0 (0%) 0 (0%) 0 (0%)
1 40 (44.9%) 28 (31.5%) 13 (14.6%)
2 25 (28.1%) 12 (13.5%) 44 (49.4%)
3 20 (22.5%) 20 (22.5%) 19 (21.3%)
4 3 (3.4%) 14 (15.7%) 6 (6.8%)
5 1 (1.1%) 15 (16.8%) 7 (7.9%)
Mean  SD 1.9 0.95 2.8 1.56 2.4 1.11
Values are n (%) except as noted.
CHADS2 Congestive heart failure; Hypertension; Age75; Diabetes mellitus; Stroke, transient
schemic attack, thromboembolic event; CHA2DS2-VASc  Congestive heart failure; Hypertension;
Age 75; Diabetes mellitus; Stroke, transient ischemic attack, thromboembolic event; Vascular
disease; Age 65 to 74; Sex category (female); HAS-BLED  Hypertension; Abnormal renal/liver
function; Stroke; Bleeding history or predisposition; Labile international normalized ratio; Elderly;
Drugs (including aspirin, nonsteroidal anti-inflammatory drugs)/alcohol concomitantly.ligation procedure and was not on aspirin. The patient was
treated with warfarin to resolve the thrombus.
Immediate closure was not achieved in 4 patients. One
patient had pericardial adhesions in the LAA sulcus pre-
cluding placement of the LARIAT device at the LAA base;
the procedure was aborted in this patient. Another patient
had his procedure aborted due to the inability to perform a
transseptal puncture. In 2 patients, LAA ligation was
aborted due to pericardial access–related complications.
One patient had a right ventricular puncture (which was
dilated over the guidewire, with consequent hemopericar-
dium), requiring drainage and observation. The second
epicardial access complication was a laceration of a superfi-
cial epigastric vessel leading to bleeding at the skin puncture
site. This epigastric vessel laceration required cauteriza-
tion to stop the bleeding. A third complication occurred
during the transseptal catheterization, resulting in perfo-
ration and hemopericardium. Since epicardial access was
in place, the hemopericardium was successfully drained.
After observation to assess for additional hemopericar-
dium, the LAA ligation was completed, and heparin was
subsequently reversed with protamine sulfate. Significant
pericardial effusion was defined as 100 ml of fluid
aspirated during the procedure. There were no device-
related complications.
Sixty-eight of 85 patients required only 1 pericardial
access attempt, whereas 17 of 85 patients required 2 pericardial
access attempts to obtain the proper orientation to deliver the
ved and treated 90 days later. LAA  left atrial appendage; OAC  oral anticoag-l resolLARIAT snare over the LAA (Fig. 6). The predominant
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pericardial access being too posterior or too medial.
All LAAs had discrete necks with 1 to 4 lobes of multiple
shapes and orientations. Successful connection of the endo-
cardial and epicardial magnet-tipped guidewires was accom-
plished immediately in 68% of the cases on the first attempt;
and within 1 min in 91% of the cases. The mean time to
connect the magnet-tipped guidewires was 1.4  0.64 min.
ime to connect the magnet-tipped guidewires began with
he insertion of epicardial guidewire into the guide sheath.
Only 1 case took more than 3 min to connect the
agnet-tipped guidewires. TEE guidance was used to
LAA Ligation Results (N  89)Table 3 LAA Ligation Results (N  89)
Successful ligation 85 (96%)
Complications 3 (3.3%)
Device related 0 (0%)
Access related 3 (3.3%)
Pericardial access 2 (2.2%)
Transseptal access 1 (1.1%)
Inability to complete ligation
Pericardial adhesions in LAA sulcus 1 (1.1%)
End-of-procedure closure (n  85)
Complete or 1-mm leak 82 (96%)
2-mm leak 2 (3%)
3-mm leak 1 (1%)
1 day post-procedure closure by TEE (n  85)
Complete or 1-mm leak 81 (95%)
2-mm leak 3 (4%)
3-mm leak 1 (1%)
30 days post-procedure closure by TEE (n  85)
Complete or 1-mm leak 81 (95%)
2-mm leak 3 (4%)
3-mm leak 1 (1%)
90 days post-procedure closure by TEE (n  81)
Complete or 1-mm leak 77 (95%)
2-mm leak 3 (4%)
3-mm leak 1 (1%)
1 year post-procedure closure by TEE n  65
Complete or 1-mm leak 64 (98%)
2-mm leak 1 (2%)
Rhythm, pre-ligation
Sinus rhythm 57 (64%)
Atrial fibrillation 29 (33%)
Atrial flutter 3 (3%)
Not available 0
Rhythm, post-ligation
Sinus rhythm 56 (63%)
Atrial fibrillation 30 (34%)
Atrial flutter 2 (2%)
Not available* 1 (1%)
Procedural time, min 45 (36–55)
Fluoroscopy time, min) 13.6 6.5
Values are n (%), median (interquartile range), or mean  SD. *The post-procedure rhythm for 1
atient was not available. This patient had a complication of right ventricular puncture and aborted
eft atrial appendage ligation.
IQR  interquartile range; LAA  left atrial appendage; TEE  transesophageal
chocardiogram.roperly position the LARIAT snare in all patients. Properpositioning of the LARIAT snare to allow LAA capture
was achieved in 68%, 94%, and 97% of the patients on the
1st attempt, 2nd attempt, and 3rd attempt, respectively. A
maximum of 4 attempts at positioning the LARIAT snare
was required in 3% of patients. There was no change in
color flow Doppler within the left upper pulmonary vein
during inflation of the balloon or closure of the snare,
consistent with initial findings (22).
The median time to capture the LAA was 4.0 min (IQR:
2 to 8 min). Time to capture was defined as the time of
introduction of LARIAT suture delivery device into the
pericardial space to placement of the LARIAT over the
LAA. An LA angiogram was performed after closure of
the LARIAT snare and prior to release of the pre-tied
suture to ensure that no lobe or remnant trabeculated LAA
was present (Fig. 3E). LA angiogram after LAA ligation
did not reveal any remnant trabeculated LAA or diverticu-
lum (Fig. 3F). The median procedural time was 45 min
(IQR: 36 to 55 min), whereas the mean fluoroscopy time
was 13.6  6.5 min.
The rhythm prior to and at the conclusion of the
procedure was not significantly different (Table 3). Prior to
the procedure, 57 (64%), 29 (33%), and 3 (3%) patients were
in AF, atrial flutter, and sinus rhythm, respectively. At the
conclusion of the procedure, 56 (63%), 30 (34%), and 2
(2%) patients were in AF, atrial flutter, and sinus rhythm,
respectively. The post-procedure rhythm for 1 patient was
not available after the patient’s ligation was complicated by
a right ventricular puncture with an aborted ligation.
Post-operatively, 20 of the 85 patients developed chest
pain following the procedure. However, once the pigtail
catheter was removed the day following the LAA ligation,
the chest pain resolved in all but 2 of the patients. The
diagnosis of pericarditis was made in these 2 patients. The
patients were treated with a nonsteroidal anti-inflammatory
drug with resolution of their pain in 2 to 3 days. One of the
patients diagnosed with pericarditis had severe chest pain
associated with ST-segment elevation in the precordial
leads. The patient underwent coronary angiography and was
found to have normal coronary anatomy. There were no
significant pericardial effusions noted during the post-
operative hospitalization. One patient developed a late
pericardial effusion 2 weeks after the LAA ligation. The
patient presented with shortness of breath. Echocardiogra-
phy did not reveal tamponade physiology. Pericardiocentesis
was performed with resolution of the patient’s symptoms.
Clinical follow-up at 6 months revealed 2 significant adverse
events. One patient had a sudden cardiac death following a
hospitalization unrelated to the procedure. The event oc-
curred 3 months after the LAA ligation procedure. The
patient presented with weakness. The patient was not in
congestive heart failure. Subsequent work-up did not find
any abnormal findings. The patient was discharged to
home. No autopsy was performed following the patient’s
death. The second adverse event was a hemorrhagic stroke
that occurred 6 months after the patient’s LAA was ligated.
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resonance imaging of the head and was presumably second-
ary to an aneurysm. Warfarin was stopped after the proce-
dure, and the patient was in sinus rhythm. The patient
recovered from the neurological event.
At the 1-year clinical follow-up, there were 2 additional
adverse events. A second patient death occurred in a patient
who had previously been diagnosed with significant
bradycardia and who refused pacemaker implantation.
Death in this patient was presumed to be an arrhythmic
death and occurred 12 months after LAA ligation. The
other patient had a lacunar stroke related to a hyperten-
sive crisis 14 months after LAA ligation. The patient had
stopped her antihypertensive medications and was in
sinus rhythm. Fifty-five percent of patients were on
warfarin therapy at the end of 1 year. There were no
thromboembolic events during the follow-up period.
Discussion
The percutaneous LAA ligation approach produced im-
mediate complete closure of the LAA in over 95% of our
patients, with the long-term follow-up suggesting the
closure is permanent. To our knowledge, this study is the
largest, prospective series of LAA suture closure (surgical
or percutaneous) verified with TEE with follow-up to 1
year.
Surgical literature has raised questions regarding the
Figure 6 Pericardial Access Approach
The angle of access in the anterior-posterior view (AP) (A) and lateral view (B).reliability of suture ligation to completely exclude the LAA.Endocardial suture ligation is incomplete in 10% to 30% of
patients, predisposing the patient to thromboembolic events
(30–32). Potential reasons for incomplete closure include:
1) the procedure is performed when the heart is in a flaccid
state during cardiopulmonary bypass; 2) the access for
suturing can be awkward; and 3) LAA closure cannot be
verified until the patient is off cardiopulmonary bypass
(22,30–32). The morbidity of cardiopulmonary bypass with
the potential for stroke, rebleeding, and respiratory failure
(33) can be prohibitive and preclude revision of a suboptimal
closure result.
Exclusion of the LAA with epicardial suture ligation or
surgical staplers is possible without cardiopulmonary bypass
(34). However, epicardial suture closure ranges from 23% to
100% (20,30–32,35–37), whereas reported LAA closure
rates using surgical staplers range from 0% to 80% (20,35).
Procedural and anatomical variables leading to incomplete
epicardial suture ligation include operator variability with
suture tightening, the presence of prosthetic mitral valves or
annuloplasty rings, and the complex anatomy of the LAA
ostium (38). The linear orientation of the surgical stapler
may not be ideal for LAA exclusion if the desired outcome
is closure at the LAA ostium. Studies have demonstrated a
post-closure diverticulum of 1 cm is not unusual, with
concern that this diverticulum may predispose to thrombus
formation (20,22). Complications most commonly observed
with the epicardial approach are tearing of the LAA (7% to
25%) leading to bleeding complications (20,31,34,36,39).
p
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grasping or traction of the LAA and avoids this risk.
The success rate in complete closure of the LAA using
the LARIAT suture delivery device is likely multifactorial,
with: 1) intraprocedural TEE using color flow Doppler to
assess for an LA–LAA leak; 2) contrast fluoroscopy to rule
out any remnant LAA; 3) the ability to open the snare and
reposition the snare before tightening the pre-tied suture;
and 4) the reduction in operator variability with use of the
TenSURE knot-tightening device. Finally, the screening
CT also provides valuable data regarding the LAA anatomy.
The CT identified 16 of 119 (13.4%) patients whose LAA
size, shape, and/or orientation excluded them from LAA
ligation. In comparison, in the LAAOS (Left Atrial Ap-
pendage Occlusion Study), 21% of patients were excluded
from surgical exclusion based on the surgeon’s assessment of
the LAA—due to size or inability to access (20). The
approach described in this study is superior to existing
surgical methods that define successful closure as no com-
munication of flow and a 1-cm nontrabeculated stump
(20,35). Compared with percutaneous implants that con-
sider closure success as 2- to 3-mm residual flow, the
approach described in this study is 100% effective versus
implant effectiveness of 86% (23).
The safety profile of the percutaneous LAA ligation
procedure is favorable compared with other LAA exclusion
procedures (23,35–37). The predominant periprocedural
adverse event associated with the percutaneous LAA liga-
tion procedure was chest pain. However, the incidence of
persistent pericarditis was 2.4%. This was treated with
nonsteroidal anti-inflammatory drugs. The late pericardial
effusion was most likely due to an inflammatory reaction
similar to Dressler’s syndrome.
The LARIAT snare device avoids potential complica-
tions anticipated with other nonsurgical approaches to
exclude the appendage. Although initial experience with the
Watchman device (Atritech, Plymouth, Minnesota) was
complicated by device embolization, perforation, or erosion
resulting in pericardial effusions, the Continued Access
Protocol for the Watchman device had fewer complications
with increased operator experience (23,24). Warfarin ther-
apy is necessary to prevent thrombus formation as the
implant surface endothelializes. Additionally, oral anticoag-
ulation may be crucial for prevention of chronic thrombus
formation and thromboembolic events in patients with a
significant peri-device leak (41). Although the risk of device
embolization is averted with epicardial LAA ligation, ob-
taining pericardial access for the LARIAT procedure is
associated with its own inherent risks, including right
ventricular puncture, epicardial vessel injury, sheath-related
trauma, and post-procedure pericarditis (42,43). Patient
selection (exclusion of patients with previous cardiac surgery
and pectus excavatum) and use of pre-procedural cardiac
CT scans may account for the lower incidence of major
pericardial access complications (2.2%) in this study com-
pared with published multicenter experience for epicardialVT ablation (7%) (43). Other percutaneous epicardial ap-
proaches for LAA closure require grasping or traction to
snare the LAA (44,45). Potential complications include
laceration of the LAA, trauma to the epicardial surface of
the myocardium, and incomplete closure due to the inability
to reposition the snare.
Clinical implications. Prevention of thromboembolic
events has become one of the cornerstones of AF treatment
regardless of a rhythm or rate control strategy (46). At least
20% of all ischemic strokes and more than a third of
ischemic strokes in the elderly are associated with AF
(47–50). About 1 in 3 people with AF will experience a
stroke in their lifetime (51–53). Despite the development
and greater awareness of newer oral anticoagulation agents,
there will always be patients with a contraindication to oral
anticoagulation therapy. Long-term bleeding risks can be
mitigated with successful suture exclusion of the LAA.
Additionally, complete closure of the LAA may allow for
safer anticoagulation strategies, such as apixaban, low-dose
dabigatran and/or aspirin, which are associated with lower
bleeding rates than high-dose dabigatran or warfarin
(8,12,14).
The medical justification for the LAA closure procedure
is based on the lack of alternative therapies for stroke
prevention in patients with a contraindication to anticoag-
ulation therapy. In patients with a higher risk for stroke
(CHADS2 score 2), recommended guidelines state that
atients should be treated with anticoagulation therapy if it
an be tolerated, regardless of the successful maintenance of
inus rhythm (16,54). Novel algorithms, such as the
HA2DS2-VASc score, may successfully identify “low-
risk” patients at risk of thromboembolic events (28); how-
ever, it does not assess a patient’s risk of bleeding compli-
cations with anticoagulation therapy.
A prospective, randomized clinical trial would provide
definitive proof that LAA exclusion would prevent throm-
boembolic events. However, there is suggestive surgical data
that complete LAA ligation is effective in preventing
embolic stroke (55). It is well known that post-operative AF
is a highly independent risk factor for stroke, with rates
between 2% and 7% in patients undergoing coronary bypass
(56,57). As part of the maze procedure, the LAA is
surgically ligated and excised. There was a large percentage
of post-operative AF in these patients, but only a 0.7% rate
of stroke (55). A follow-up study on 178 patients undergo-
ing a Cox Maze III procedure with discontinuation of
warfarin reported that none of the patients had a stroke 10
years after surgery (21). Additionally, the Watchman device
for LAA exclusion compared with warfarin therapy dem-
onstrated noninferiority of the occlusion device (23). Given
the current data, percutaneous LAA ligation may be a
complementary alternative to oral anticoagulation and the
Watchman device for thromboembolic event risk reduction.
However, no definitive statement can be made regarding
stroke reduction without prospective studies. A noninferiority
trial comparing the LARIAT device to oral anticoagulation
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patients with supportive data for LAA ligation as an alternative
therapy for thromboembolic event risk reduction.
Study limitations. The study is a nonrandomized, single-
center trial. Much of the experience was concentrated with
several operators, thus potentially skewing the efficiency of
performing the procedures. The assessment of LAA closure
by TEE might be overestimated due to AF resulting in
decreased inflow and outflow velocities in the LAA. This
may result in the lack of detection of small communications
between the LA and a sutured LAA by color flow or
spectral Doppler flow assessment. However, the initial
operators did not have experience with either pericardial
access or transseptal catheterization at the onset of the
study, thus demonstrating the ease of adoption of the
procedure. Long-term results for thromboembolic event
reduction are confounded by the high proportion (61%) of
patients on warfarin at the time of last follow-up. Future
prospective studies will require a systematic protocol for
discontinuing anticoagulation by a pre-specified time point
to accurately assess the long-term risk reduction for throm-
boembolic events following LAA ligation.
Conclusions
The percutaneous catheter-based LAA ligation procedure
using the LARIAT suture delivery device is feasible and
effective in humans and produces complete closure of the
LAA verified by serial TEE. This observational study
provides evidence of the reliability of LAA exclusion with
acceptably low access complications and adverse events;
enabling this percutaneous LAA ligation procedure to be
used in future randomized clinical trials to determine
whether LAA exclusion prevents thromboembolic events in
patients with AF.
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